10YX
10YX is a cyclic peptide probe targeting glypican-3 (GPC3) (Kd = 300.4 nM for human GPC3). It achieves tumor targeting by binding to GPC3 sitemap2 and serves as a PET imaging probe for tumor visualization and intrahepatic lesion localization. 10YX is useful for research on hepatocellular carcinoma.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Formule: C83H124N22O25S2
- Masse moléculaire:1894.14
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
In Vitro
10YX (10 μM) binds to recombinant human GPC3 with a dissociation constant (Kd) of 300.4 nM[1].
10YX binds to the predicted GPC3 binding site, and the highest-ranked docking conformation has a score of -6.664[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
10YX (150-200 μCi; i.v.) exhibits a peak tumor uptake of 2.73% ID/g at 30 min and higher renal retention (45.41% ID/g at 4 h) in HepG2 tumor-bearing mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
Masse moléculaire 1894.14
-
Formule C83H124N22O25S2
-
Sequence
AC-{Lys(PAMBA-DOTA)}-Cys-Leu-Asn-His-Glu-Leu-Phe-Gln-Thr-Cys-NH2 (Disulfide bridge: Cys2-Cys11)
-
Sequence Shortening
AC-{Lys(PAMBA-DOTA)}-CLNHELFQTC-NH2 (Disulfide bridge: Cys2-Cys11)
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Liver Cancer Modeling
Liver cancer can be classified into primary liver cancer and secondary liver cancer. Secondary liver cancer is the metastatic liver cancer. Primary liver cancer includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and fibrolamellar HCC, of which HCC is the most common form, accounting for approximately 90% of primary liver cancers[1]. HCC mouse models include chemical agent-induced models, transplanted tumor models, and genetic engineered models.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
10YX Related Classifications
HY-P11969 Related Classifications
Powered by Bioz